Currently, 1,3-diaryl pyrazole derivatives were found to have significant inhibitory power and sensitivity to COX-2 enzyme and significant anti-inflammatory activity against COX-1 compared to celecoxib and indomethacin, and have dual anti-inflammatory and anti-cancer activity for the treatment of CRC 132. The gene discussed is PTGS2; the disease is colorectal carcinoma.